KIT
2 EU-approved indications of 1 drug need a KIT result, in 1 tumour type, most of them in gastrointestinal stromal tumour.
Approved indications2
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Gastrointestinal stromal tumour2 | ||||
Glivec | Monotherapy | Adj. | After resection of Kit (CD117)-positive GIST; Significant risk of relapse; patients who have a low or very low risk of recurrence should not receive adjuvant treatment | |
Glivec | Monotherapy | Any line advanced | None | |
KIT by tumour
Label wording2
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Imatinib (Glivec)
the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
- Imatinib (Glivec)
the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.